Immunomodulatory Effects of Vitamin D: Implications for the Prevention and Treatment of Graft Versus Host Disease

Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Whitney Keefe(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Nataliya Rozenvayn, Dimitrios Tzachanis(Dana-Farber Cancer Institute), Corrine Zarwan(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute)
Blood
November 16, 2008
10.1182/blood.v112.11.1251.1251
Cited by 1

Related Papers

PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k